Literature DB >> 2887331

Leucopenia in adult Still's disease during treatment with azathioprine and sulphasalazine.

H Bliddal, P Helin.   

Abstract

The experience is reported concerning treatment of adult Still's disease with a combination of azathioprine and sulphasalazine. In three patients a favourable effect on the symptoms was noted. In one of these patients a year-long prednisone treatment was withdrawn and replaced by sulphasalazine. In all these cases, however, a decrease was seen in leucocyte counts to subnormal levels after the addition of sulphasalazine to a basis therapy with azathioprine 150-200 mg/d (2.1-3.3 mg/kg). The effect was only transitory in two patients, while it lasted several months in the third. In a fourth patient agranulocytosis developed after four days following the combined treatment with azathioprine 150 mg/d (2.3 mg/kg) and 250-1000 mg/d (4-15 mg/kg) of sulphasalazine, lasting four days before recovery. A later resumption of the combination therapy with these same drugs, but in a lower dosage, did not induce any acute changes in leucocyte counts. The skin rash provoked by sulphasalazine in two of the patients did not recur after desensitization. It is concluded, that this combination therapy is valuable in adult Still's disease, but that caution should be exerted during the initiation of sulphasalazine therapy. This should be monitored by daily measurements of leucocyte counts in the first weeks and preferably started by the use of a desensitising kit.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887331     DOI: 10.1007/bf02201031

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  Adult-onset Still's disease. Disease course and HLA associations.

Authors:  J M Wouters; P Reekers; L B van de Putte
Journal:  Arthritis Rheum       Date:  1986-03

2.  Still's disease in the adult.

Authors:  E G Bywaters
Journal:  Ann Rheum Dis       Date:  1971-03       Impact factor: 19.103

3.  Sulphasalazine in rheumatoid arthritis: an old drug revived.

Authors:  V C Neumann; K A Grindulis
Journal:  J R Soc Med       Date:  1984-03       Impact factor: 5.344

4.  Mode of action of sulphasalazine: an alternative view.

Authors:  A T Ali; G S Basran; J Morley
Journal:  Lancet       Date:  1982-02-27       Impact factor: 79.321

Review 5.  Cytotoxic drugs: their clinical application to the rheumatic diseases.

Authors:  P J Clements; J Davis
Journal:  Semin Arthritis Rheum       Date:  1986-05       Impact factor: 5.532

6.  Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash.

Authors:  D E Bax; R S Amos
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

7.  Antifolate actions of sulfasalazine on intact lymphocytes.

Authors:  C L Baum; J Selhub; I H Rosenberg
Journal:  J Lab Clin Med       Date:  1981-06

8.  Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

Authors:  V C Neumann; K A Grindulis; S Hubball; B McConkey; V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

9.  Neutropenia in patients with inflammatory arthritis treated with sulphasalazine.

Authors:  M Farr; D P Symmons; D R Blake; P A Bacon
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.